Adaptive Immune Response Platform for Diverse Disease Treatment
Legal Citation
Summary of the Inventive Concept
The inventive concept leverages the core technology of the original patent to develop novel applications in treating respiratory diseases, preventing influenza, and addressing neurodegenerative and cardiovascular diseases, as well as preventing HIV.
Background and Problem Solved
The original patent focused on treating bladder cancer using Bacillus Calmette-Guerin (BCG) and antigen presenting cells. However, the current inventive concept expands this technology to tackle a broader range of diseases, addressing the limitations of the original patent in terms of disease scope and treatment options.
Detailed Description of the Inventive Concept
The inventive concept revolves around administering vaccine compositions comprising immunotherapeutic primed antigen presenting cells and IL-15:IL-15Rα fusion protein complexes to subjects with diverse diseases. These compositions stimulate or enhance immune responses to specific disease-causing pathogens or agents, thereby providing a therapeutic effect. The antigen presenting cells are isolated from subjects with the respective diseases, and the IL-15:IL-15Rα fusion protein complex is tailored to stimulate an immune response specific to each disease.
Novelty and Inventive Step
The new claims introduce a paradigm shift in applying the core technology to entirely new disease areas, including respiratory diseases, influenza, neurodegenerative diseases, cardiovascular diseases, and HIV prevention. This inventive step lies in the recognition that the original technology can be adapted to address a wide range of diseases, leveraging the flexibility of the antigen presenting cells and IL-15:IL-15Rα fusion protein complex.
Alternative Embodiments and Variations
Alternative embodiments may include modifying the antigen presenting cells or IL-15:IL-15Rα fusion protein complex to target specific disease subtypes or using different routes of administration. Variations may also involve combining the vaccine compositions with other immunotherapies or adjuvants to enhance treatment efficacy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, targeting a broad range of diseases with high unmet medical needs. The market potential spans across multiple therapeutic areas, including respiratory, infectious, neurodegenerative, and cardiovascular diseases, as well as HIV prevention.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/04 |
| A | A61 | A61K35/15 |
| A | A61 | A61K39/00114 |
| A | A61 | A61K39/001119 |
| A | A61 | A61K39/39 |
| A | A61 | A61K2039/515 |
| A | A61 | A61K2039/585 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy and vaccine development, specifically focused on antigen presenting cell (APC) manipulation and cytokine-based immune modulation for treating various diseases
Person of Ordinary Skill (PHOSITA) Profile
A skilled immunologist or biomedical researcher with expertise in cellular immunology, vaccine design, and cytokine signaling, holding a PhD or equivalent advanced scientific training with experience in developing immunotherapeutic approaches
Obviousness Rationale
A person skilled in the art would recognize that the core immunological mechanism of using antigen presenting cells with IL-15:IL-15Rα fusion protein complexes is fundamentally transferable across different disease contexts. The source patent establishes a generalizable platform for immune stimulation that can be systematically adapted to target diverse disease pathologies by simply modifying the source of antigen presenting cells and tailoring the immune response parameters.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,612 |
|---|---|
| Title | Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer |
| Assignee(s) | NantCell, Inc. |